FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128270329> ?p ?o ?g. }

• W2128270329 endingPage "368" @default.
• W2128270329 startingPage "361" @default.
• W2128270329 abstract "<h3>Objective</h3> To evaluate the cost-effectiveness of personalised treatment for rheumatoid arthritis (RA) using clinical response and serum adalimumab levels. <h3>Methods</h3> A personalised treatment algorithm defined, based on clinical (European League Against Rheumatism) response and drug levels at 6 months, whether adalimumab treatment should be continued in a specific dose or discontinued and/or switched to a next biological. Outcomes were simulated using a patient level Markov model, with 3 months cycles, based on a cohort of 272 adalimumab-treated patients with RA for 3 years and data of patients from the Utrecht Rheumatoid Arthritis Cohort. Costs, clinical effectiveness and quality adjusted life years (QALYs) were compared with outcomes as observed in usual care and incremental cost-effectiveness ratios were calculated. Analyses were performed probabilistically. <h3>Results</h3> Clinical effectiveness was higher for the cohort simulated to receive personalised care compared with usual care; the average difference in QALYs was 3.84 (95 percentile range −8.39 to 16.20). Costs were saved on drugs: €2 314 354. Testing costs amounted to €10 872. Mean total savings were €2 561 648 (95 percentile range −3 252 529 to −1 898 087), resulting in an incremental cost-effectiveness ratio of €666 500 or €646 266 saved per QALY gained from a societal or healthcare perspective, respectively. In 72% of simulations personalised care saved costs and resulted in more QALYs, in 28% it was cost saving with lower QALYs. Scenario analyses showed cost saving along with QALYs gain or limited loss. <h3>Conclusions</h3> Tailoring biological treatment to individual patients with RA starting adalimumab using drug levels and short-term outcome is cost-effective. Results underscore the potential merit of personalised biological treatment in RA." @default.
• W2128270329 created "2016-06-24" @default.
• W2128270329 creator A5016619475 @default.
• W2128270329 creator A5017043157 @default.
• W2128270329 creator A5017243329 @default.
• W2128270329 creator A5029733252 @default.
• W2128270329 creator A5042828393 @default.
• W2128270329 creator A5063928355 @default.
• W2128270329 creator A5067384016 @default.
• W2128270329 creator A5073590530 @default.
• W2128270329 creator A5075695885 @default.
• W2128270329 creator A5086661348 @default.
• W2128270329 date "2013-11-21" @default.
• W2128270329 modified "2023-10-16" @default.
• W2128270329 title "Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects" @default.
• W2128270329 cites W1965832974 @default.
• W2128270329 cites W1978593886 @default.
• W2128270329 cites W1979364075 @default.
• W2128270329 cites W1992628263 @default.
• W2128270329 cites W1996472975 @default.
• W2128270329 cites W2000905503 @default.
• W2128270329 cites W2006566716 @default.
• W2128270329 cites W2014331422 @default.
• W2128270329 cites W2027397415 @default.
• W2128270329 cites W2040827109 @default.
• W2128270329 cites W2085411350 @default.
• W2128270329 cites W2091685587 @default.
• W2128270329 cites W2101168807 @default.
• W2128270329 cites W2106825961 @default.
• W2128270329 cites W2108650270 @default.
• W2128270329 cites W2110177517 @default.
• W2128270329 cites W2110732019 @default.
• W2128270329 cites W2111046066 @default.
• W2128270329 cites W2118559127 @default.
• W2128270329 cites W2123170396 @default.
• W2128270329 cites W2123352987 @default.
• W2128270329 cites W2141171232 @default.
• W2128270329 cites W2148989961 @default.
• W2128270329 cites W2149065814 @default.
• W2128270329 cites W2272291172 @default.
• W2128270329 cites W2314052274 @default.
• W2128270329 cites W2318993912 @default.
• W2128270329 cites W4252809665 @default.
• W2128270329 cites W4295125684 @default.
• W2128270329 doi "https://doi.org/10.1136/annrheumdis-2013-204101" @default.
• W2128270329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24265411" @default.
• W2128270329 hasPublicationYear "2013" @default.
• W2128270329 type Work @default.
• W2128270329 sameAs 2128270329 @default.
• W2128270329 citedByCount "76" @default.
• W2128270329 countsByYear W21282703292014 @default.
• W2128270329 countsByYear W21282703292015 @default.
• W2128270329 countsByYear W21282703292016 @default.
• W2128270329 countsByYear W21282703292017 @default.
• W2128270329 countsByYear W21282703292018 @default.
• W2128270329 countsByYear W21282703292019 @default.
• W2128270329 countsByYear W21282703292020 @default.
• W2128270329 countsByYear W21282703292021 @default.
• W2128270329 countsByYear W21282703292022 @default.
• W2128270329 countsByYear W21282703292023 @default.
• W2128270329 crossrefType "journal-article" @default.
• W2128270329 hasAuthorship W2128270329A5016619475 @default.
• W2128270329 hasAuthorship W2128270329A5017043157 @default.
• W2128270329 hasAuthorship W2128270329A5017243329 @default.
• W2128270329 hasAuthorship W2128270329A5029733252 @default.
• W2128270329 hasAuthorship W2128270329A5042828393 @default.
• W2128270329 hasAuthorship W2128270329A5063928355 @default.
• W2128270329 hasAuthorship W2128270329A5067384016 @default.
• W2128270329 hasAuthorship W2128270329A5073590530 @default.
• W2128270329 hasAuthorship W2128270329A5075695885 @default.
• W2128270329 hasAuthorship W2128270329A5086661348 @default.
• W2128270329 hasBestOaLocation W21282703292 @default.
• W2128270329 hasConcept C105795698 @default.
• W2128270329 hasConcept C112930515 @default.
• W2128270329 hasConcept C122048520 @default.
• W2128270329 hasConcept C126322002 @default.
• W2128270329 hasConcept C1862650 @default.
• W2128270329 hasConcept C2777575956 @default.
• W2128270329 hasConcept C2780132546 @default.
• W2128270329 hasConcept C3019080777 @default.
• W2128270329 hasConcept C33923547 @default.
• W2128270329 hasConcept C64332521 @default.
• W2128270329 hasConcept C71924100 @default.
• W2128270329 hasConcept C72563966 @default.
• W2128270329 hasConceptScore W2128270329C105795698 @default.
• W2128270329 hasConceptScore W2128270329C112930515 @default.
• W2128270329 hasConceptScore W2128270329C122048520 @default.
• W2128270329 hasConceptScore W2128270329C126322002 @default.
• W2128270329 hasConceptScore W2128270329C1862650 @default.
• W2128270329 hasConceptScore W2128270329C2777575956 @default.
• W2128270329 hasConceptScore W2128270329C2780132546 @default.
• W2128270329 hasConceptScore W2128270329C3019080777 @default.
• W2128270329 hasConceptScore W2128270329C33923547 @default.
• W2128270329 hasConceptScore W2128270329C64332521 @default.
• W2128270329 hasConceptScore W2128270329C71924100 @default.
• W2128270329 hasConceptScore W2128270329C72563966 @default.
• W2128270329 hasIssue "2" @default.
• W2128270329 hasLocation W21282703291 @default.

• next